Pubblicazioni Scientifiche
Dermatologia29 ott 2020
Expanding treatment options for rosacea
Such a high-quality cluster randomized controlled trial involving 2040 nurses across the UK.
29 ott 2020
Dermoscopy of genital diseases: a review
A review
20 ott 2020
Immunogenicity of biologic therapies in psoriasis Myths, facts and a suggested approach
With biologic drugs dominating the therapeutic space for severe immune‐mediated inflammatory disease, it is critical for clinicians to be familiar with the concept of drug immunogenicity, with the potential for our patients to develop anti‐drug antibodies (ADA) of clinical relevance.
20 ott 2020
Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
Dupilumab, an inhibitor of interleukin (IL)‐4/13 activity, is a biological agent approved for the treatment of moderate‐to‐severe atopic dermatitis (AD)
20 ott 2020
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis
Is exposure to topical calcineurin inhibitors among adult patients with atopic dermatitis associated with increased keratinocyte carcinoma risk?
11 ott 2020
No increased risk of melanoma among patients with psoriasis treated with methotrexate
Patients with an impaired immune system have higher risk for melanoma, the most dangerous type of skin cancer, and a worse prognosis.
11 ott 2020
New jak inhibitors for the treatment of psoriasis and psoriatic arthritis
Psoriasis is a common inflammatory skin disease that can be associated with various pathological conditions among which arthritis is a frequent comorbidity.
11 ott 2020
A retrospective cohort study of the diagnostic value of different subtypes of atypical pigment network on dermoscopy
Atypical network encompasses several patterns.
06 ott 2020
Challenges and new perspectives in the treatment of advanced cutaneous squamous cell carcinoma
an expert opinion
06 ott 2020
Systematic Review of Mohs Micrographic Surgery in Children
Identifying Challenges and Practical Considerations for Successful Application
06 ott 2020
What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice?
A prospective observational study
28 set 2020
An Overview of Uncommon Cutaneous Malignancies, Including Skin Appendageal (Adnexal) Tumours and Sarcomas
The review is based on a search of peer-reviewed publications found using PubMed search tools and including the keywords identified above. In addition, the reference lists from other key articles were used to obtain other pertinent articles.
28 set 2020
Photosensitivity and cancer immune-targeted therapies
adverse drug reaction, cancer, immune therapy, photoallergic, photosensitivity, phototoxic, reaction
28 set 2020
Overview on the treatment of Lyme disease in pregnancy
Lyme disease is a tick-borne illness, which is typically caused by Borrelia Burgdoferi
22 set 2020
Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitis
Atopic dermatitis (AD) is an inflammatory disease with a chronic-relapsing course that is intensely itchy.
22 set 2020
Technological advances for the detection of melanoma
Advances in diagnostic techniques
21 set 2020
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology
Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin.
14 set 2020
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life.
14 set 2020
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab
Is the risk of severe cardiovascular events increased after the initiation of treatment with the anti–interleukin 12/23p40 (IL-12/23p40) monoclonal antibody ustekinumab?
14 set 2020
A phase 2, open‐label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis
pharmacokinetics, safety and efficacy